N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,036 A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 — -1.13; -1.10 percent of hemoglobin — p=0.6273
Phase 2 N=11 Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.
Myelodysplastic Syndromes
Primary: Number of Participants With Adverse Events (AE) — 11; 11; 11; 11 participants
Phase 2 N=74 Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Number of Patients With Adverse Events (AEs) — 64; 1; 5; 16 participants
Phase 2 N=57 Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
Multiple Myeloma
Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants
Phase 4 N=64 Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
Allergic Rhinitis
Primary: Total Nasal Congestion Symptom Score — 94; 70; 75; 68 units on a scale
N/A N=13 Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)
Scedosporium Infection
Primary: Number of Participants With Serious Treatment Related Adverse Events. — 2 participants
Phase 1 N=65 Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Phase 2 N=81 Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: The Primary Safety and Tolerability Outcome Measure is Reported Adverse Events. — 81 participants
Phase 4 N=251 A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children
Hepatitis A
Primary: Seroprotection at Month 1 — 95.9; 96.6 percentage of participants
Phase 2 N=426 Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Change From Baseline in MADRS Total Score After 6 Weeks of Treatment — -14.50; -20.40; -20.20; -20.92 units on a scale — p=<0.0001
N/A N=70 The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position
Cerebral Ischemia
Primary: Incidence of Cerebral Desaturation Events — 19; 3 number of events
Phase 3 N=94 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
Hepatitis C, Chronic
Primary: Number of Participants Who Relapsed At End of LTFU Year 5 — 0 participants
Phase 2 N=12 Belatacept Pharmacokinetic Trial in Renal Transplantation
Renal Transplantation
Primary: Mean Belatacept Serum Concentrations Between Weeks 12 and 16 by Nominal Collection Time, Following 10mg/kg IV Belatacept - Pharmacokinetic Population — 8491.00; 242667…
N/A N=5 Oxcarbazepine Versus Placebo in Childhood Autism
Autism
Primary: Vineland Adaptive Behavior Scales